Session Title: AMD I
Session Date/Time: Friday 12/09/2014 | 08:00-10:00
Paper Time: 09:36
Venue: Boulevard C
First Author: : A.Loewenstein ISRAEL
Co Author(s): : H.
Use of the ForeseeHome plus standard care monitoring in people at high risk of AMD progression has been demonstrated to detect choroidal neovascularization (CNV) earlier than standard care monitoring alone. The purpose of this presentation is to describe clinical features of early CNV as determined by a reading center based on fluorescein angiography (FA) and optical coherence tomography (OCT).
Multicentered AREDS2 trial ancillary study
A comparative analysis of FA and OCT images graded by masked readers centrally in all CNV events diagnosed during the HOME study(study endpoint as determined by the clinical investigators) was performed. Comparisons were made for 3 categories: 1) CNV cases confirmed by FA and/or OCT, 2) CNV cases confirmed by FA only and 3) CNV cases confirmed by OCT only.
For the first category, median and mean (SD) lesion size were 0.23 and 0.64 (1.04) DA, (n=39) in the device arm compared to 0.7, 1.46 (2.53), (n=23) in the control arm (p=0.05), with median change in VA from baseline of -4 and -10 letters respectively (p=0.004). For the second category, the median and mean lesion size were 0.69 and 1.09 (1.16), (n=23) in the device arm compared to 0.99, 1.77 (2.69), (n=19) in the control arm, (p=0.31), with median reduction in VA from baseline of 4 and 12 letters, respectively (p=0.006). For the third category, the median and mean Centerpoint RPE lesion complex were 76 and 108 (120) (µ), (n=29) in the device arm compared to 155, 169 (142), (n=18) in the control arm, (p=0.04), with median reduction in VA from baseline of 3 and 9 letters, respectively (p=0.005).
More favorable vision outcomes following anti-VEGF therapy of CNV lesions have been associated with small CNV lesions relative to larger lesions. The ForeseeHome enables the detection of CNV when lesion size is very small and with good VA thus increasing the likelihood of better visual outcomes following treatment.